[Prognostic markers of advanced non-small cell lung carcinoma - assessing the significance of oncomarkers using data-mining techiques RPA]
| Autor: | A Dammak, Vasilenková I, Labudová, Nádaská O, Migašová M, Grmanová E, Skarbová, Najšelová E, Dienerová M, Jurga L, Cingelová S, Berkešová D, Viktorínová Z |
|---|---|
| Jazyk: | čeština |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms Weight Lifting medicine.medical_treatment Recursive partitioning computer.software_genre Weight loss Antigens Neoplasm Internal medicine Carcinoma Non-Small-Cell Lung medicine Carcinoma Biomarkers Tumor Data Mining Humans Stage (cooking) Retrospective Studies Keratin-19 Chemotherapy Performance status business.industry medicine.disease Prognosis Comorbidity Carcinoembryonic Antigen Relative risk Phosphopyruvate Hydratase Data mining medicine.symptom business computer |
| Zdroj: | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 27(5) |
| ISSN: | 0862-495X |
| Popis: | INTRODUCTION Identification of new prognostic factors can help in designing future clinical studies. In the case of advanced non-small cell lung cancer, there might be good candidates - tumor markers CYFRA 21-1, CEA or NSE [1-8]. It is possible to evaluate the relationship between their expression and prognosis by data mining technique recursive partitioning and amalgamation. PATIENTS AND METHODS We analyzed retrospective data of 162 patients of Oncology clinics in Trnava. All of these patients were admitted between 2008 and 2012 for the administration of first-line chemotherapy according to current recommendations. We evaluated the impact of known pretreatment prognostic markers - performance status, weight loss, smoking, age, sex, stage, histologic subtype, comorbidity and oncomarkers CYFRA 21-1, CEA or NSE, as well as combinations of these factors on survival. RESULTS Our analyses showed that there are three subgroups of patients with good, intermediate and unfavorable prognosis. Oncomarkers played an important role in formation of a subgroup of 49 patients with good prognosis - including patients with no pretreatment weight loss and low levels of CEA ( 4.1 ng/ml) or NSE ( 11.1 ng/ml). In this subgroup, the median survival time was at least 16 months (not achieved) and the difference in survival compared to the rest of the group was highly statistically significant (risk ratio 5.21, 95% CI 1.41-19.28; p < 0.0001). CONCLUSION We showed the prognostic significance of low levels of NSE and CEA oncomarkers in the group of patients with no pretreatment weight loss. Recursive partitioning and amalgamation is a useful data mining method, but the generated hypothesis needs to be confirmed by further clinical study designed for this purpose |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|